60 Degrees Pharmaceuticals Will Be Issued US Patent Number 12,691,107 Tomorrow Titled "METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE".

60 Degrees Q2 EPS $(0.90) Misses $(0.86) Estimate, Sales $56.798K Miss $186.000K Estimate

60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.86) by 4.65 percent. This is a 82.04 percent increase over losses of $(5.01) per share from the

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals announced a private placement of 574,713 shares at $1.74 per share, expected to raise approximately $1.0 million in gross proceeds before fees. The offering includes series A and B warrants with exercise prices of $1.49 per share. The company plans to use net proceeds for working capital and general corporate purposes.

60 Degrees Pharmaceuticals Announces $1M Private Placement Of 574,713 Shares At $1.74, Including Warrants